Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 10/2019

01.10.2019 | Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

The Complex Relationship Between Lower Urinary Tract Symptoms and Sexual Health

verfasst von: Hanson Zhao, Howard H. Kim

Erschienen in: Current Urology Reports | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Lower urinary tract symptoms (LUTS) and sexual health have common links. Medical and surgical treatments for LUTS can significantly affect various domains of sexual health including erectile function, ejaculatory function, and libido. This review summarizes recent findings.

Recent Findings

Current literature demonstrates a strong association between LUTS, sexual health, and metabolic syndrome. The role of miRNA is also being investigated. Combination medical therapy with phosphodiesterase 5 inhibitors (PDE5-I) shows promise but needs further investigation. Newer surgical therapies for benign prostatic hyperplasia (BPH) aim to preserve sexual function without sacrificing efficacy and durability.

Summary

Although we are beginning to acknowledge the link between LUTS and sexual health, a better understanding of the underlying biochemistry is needed. Only then can more effective therapies be developed. Further prospective studies should focus on the long-term durability and safety of treatments for both conditions.
Literatur
1.
De Nunzio C, et al. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus. 2017;3(4–5):352–63.CrossRefPubMed
2.
Choi WS, Heo NJ, Lee YJ, Son H. Factors that influence lower urinary tract symptom (LUTS)-related quality of life (QoL) in a healthy population. World J Urol. 2017;35(11):1783–9.CrossRefPubMed
3.
Tan HM, Tong SF, Ho CC. Men’s health: sexual dysfunction, physical, and psychological health--is there a link? J Sex Med. 2012;9(3):663–71.CrossRefPubMed
4.
Marra G, Sturch P, Oderda M, Tabatabaei S, Muir G, Gontero P. Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men's ejaculatory function: time for a bespoke approach? Int J Urol. 2016;23(1):22–35.CrossRef
5.
Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, de Nunzio C, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2015;115(1):24–31.CrossRefPubMed
6.
Besiroglu H, Otunctemur A, Ozbek E. The relationship between metabolic syndrome, its components, and erectile dysfunction: a systematic review and a meta-analysis of observational studies. J Sex Med. 2015;12(6):1309–18.CrossRefPubMed
7.
Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809–25.CrossRefPubMed
8.
Mónica FZ, Bian K, Murad F. The endothelium-dependent nitric oxide-cGMP pathway. Adv Pharmacol. 2016;77:1–27.CrossRefPubMed
9.
Lin CS, Lin G, Lue TF. Cyclic nucleotide signaling in cavernous smooth muscle. J Sex Med. 2005;2(4):478–91.CrossRefPubMed
10.
Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate. 1997;33(1):1–8.CrossRefPubMed
11.
Johansson R, et al. Activity and expression of nitric oxide synthase in the hypertrophied rat bladder and the effect of nitric oxide on bladder smooth muscle growth. J Urol. 2002;168(6):2689–94.CrossRefPubMed
12.
Merrill L, Gonzalez EJ, Girard BM, Vizzard MA. Receptors, channels, and signalling in the urothelial sensory system in the bladder. Nat Rev Urol. 2016;13(4):193–204.CrossRefPubMedPubMedCentral
13.
Christ GJ, Andersson KE. Rho-kinase and effects of rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007;26(6 Suppl):948–54.CrossRefPubMed
14.
Sopko NA, Hannan JL, Bivalacqua TJ. Understanding and targeting the Rho kinase pathway in erectile dysfunction. Nat Rev Urol. 2014;11(11):622–8.CrossRefPubMedPubMedCentral
15.
Bing W, Chang S, Hypolite JA, DiSanto ME, Zderic SA, Rolf L, et al. Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Ren Physiol. 2003;285(5):F990–7.CrossRef
16.
Kedia GT, Ückert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol. 2008;26(6):603–9.CrossRefPubMed
17.
Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice. Andrologia. 2006;38(1):1–12.CrossRefPubMed
18.
• Greco F, et al. The potential role of microRNAs as biomarkers in benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus. 2018; A systematic review of the microRNAs that are potentially implicated in BPH.
19.
Wen Y, Liu G, Zhang Y, Li H. MicroRNA-205 is associated with diabetes mellitus-induced erectile dysfunction via down-regulating the androgen receptor. J Cell Mol Med. 2019;23:3257–70.CrossRefPubMedPubMedCentral
20.
Zhang Y, Jia L, Ji W, Li H. MicroRNA-141 inhibits the proliferation of penile cavernous smooth muscle cells associated with down-regulation of the Rhoa/Rho kinase signaling pathway. Cell Physiol Biochem. 2018;48(1):348–60.CrossRefPubMed
21.
Pan F, et al. MicroRNA-200a is up-regulated in aged rats with erectile dysfunction and could attenuate endothelial function via SIRT1 inhibition. Asian J Androl. 2016;18(1):74–9.CrossRefPubMed
22.
Liu C, et al. The changes of microRNA expression in the corpus cavernosum of a rat model with cavernous nerve injury. J Sex Med. 2018;15(7):958–65.CrossRefPubMed
23.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52.CrossRefPubMed
24.
Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313(19):1973–4.CrossRefPubMed
25.
Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10):812–9.CrossRefPubMed
26.
Sanchez E, Pastuszak AW, Khera M. Erectile dysfunction, metabolic syndrome, and cardiovascular risks: facts and controversies. Transl Androl Urol. 2017;6(1):28–36.CrossRefPubMedPubMedCentral
27.
Schulster ML, Liang SE, Najari BB. Metabolic syndrome and sexual dysfunction. Curr Opin Urol. 2017;27(5):435–40.CrossRefPubMed
28.
Cellek S, Cameron NE, Cotter MA, Fry CH, Ilo D. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nat Rev Urol. 2014;11(4):231–41.CrossRefPubMed
29.
Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–41.CrossRefPubMed
30.
He Q, Wang Z, Liu G, Daneshgari F, MacLennan G, Gupta S. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis. 2016;19(1):7–13.CrossRefPubMed
31.
Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016;13(2):108–19.CrossRefPubMed
32.
Lotti F, Maggi M. Interleukin 8 and the male genital tract. J Reprod Immunol. 2013;100(1):54–65.CrossRefPubMed
33.
Liu L, Li Q, Han P, Li X, Zeng H, Zhu Y, et al. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology. 2009;74(2):340–4.CrossRefPubMed
34.
Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol. 2014;66(4):619–22.CrossRefPubMed
35.
Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, et al. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol. 2012;132(1–2):80–92.CrossRefPubMed
36.
Smith DP, Weber MF, Soga K, Korda RJ, Tikellis G, Patel MI, et al. Relationship between lifestyle and health factors and severe lower urinary tract symptoms (LUTS) in 106,435 middle-aged and older Australian men: population-based study. PLoS One. 2014;9(10):e109278.CrossRefPubMedPubMedCentral
37.
Mondul AM, Giovannucci E, Platz EA. A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms. J Urol. 2014;191(3):715–21.CrossRefPubMed
38.
Maserejian NN, Giovannucci EL, McKinlay JB. Dietary macronutrients, cholesterol, and sodium and lower urinary tract symptoms in men. Eur Urol. 2009;55(5):1179–89.CrossRefPubMed
39.
• Bradley CS, et al. Evidence of the impact of diet, fluid intake, caffeine, alcohol and tobacco on lower urinary tract symptoms: a systematic review. J Urol. 2017;198(5):1010–20 This systematic review demonstrates that fluid and caffeine intake can increase urinary urgency/frequency while modest alcohol intake may decrease LUTS. However, the overall quality of evidence is poor as most studies are observational in nature. CrossRefPubMedPubMedCentral
40.
Andersson KE. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol. 2018;175(13):2554–65.CrossRefPubMedPubMedCentral
41.
Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53(6):1236–44.CrossRefPubMed
42.
McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177(3):1071–7.CrossRefPubMed
43.
McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177(4):1401–7.CrossRefPubMed
44.
Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180(4):1228–34.CrossRefPubMed
45.
Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int. 2010;105(4):502–7.CrossRefPubMed
46.
Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol. 2010;183(3):1092–7.CrossRefPubMed
47.
Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30(3):292–301.CrossRefPubMed
48.
Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, de Vita G, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med. 2010;7(1 Pt 1):59–69.CrossRefPubMed
49.
Werkström V, et al. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int. 2006;98(2):414–23.CrossRefPubMed
50.
Lin G, Huang YC, Wang G, Lue TF, Lin CS. Prominent expression of phosphodiesterase 5 in striated muscle of the rat urethra and levator ani. J Urol. 2010;184(2):769–74.CrossRefPubMedPubMedCentral
51.
Truss MC, Stief CG, Uckert S, Becker AJ, Wefer J, Schultheiss D, et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol. 2001;19(5):344–50.CrossRefPubMed
52.
Oger S, et al. Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol. 2010;160(5):1135–43.CrossRefPubMedPubMedCentral
53.
Zenzmaier C, Kern J, Sampson N, Heitz M, Plas E, Untergasser G, et al. Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation. Endocrinology. 2012;153(11):5546–55.CrossRefPubMed
54.
Vignozzi L, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013;73(13):1391–402.CrossRefPubMed
55.
• Gacci M, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016;70(1):124–33 An excellent review of the pathophysiology and clinical evidence that support the use of PDE5-Is for BPH/LUTS. PDE5-Is are one of the only treatments to improve ED and BPH/LUTS, but their role in the algorithm for BPH/LUTS is unknown. CrossRefPubMed
56.
Ito H, Chakrabarty B, Drake MJ, Fry CH, Kanai AJ, Pickering AE. Sildenafil, a phosphodiesterase type 5 inhibitor, augments sphincter bursting and bladder afferent activity to enhance storage function and voiding efficiency in mice. BJU Int. 2019;124:163–73.CrossRefPubMedPubMedCentral
57.
Pattanaik S, et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2018;11:CD010060.PubMed
58.
Casabé A, Roehrborn CG, da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191(3):727–33.CrossRefPubMed
59.
van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66(3):287–301.CrossRefPubMed
60.
Kumar R, Nehra A, Jacobson DJ, McGree ME, Gades NM, Lieber MM, et al. Alpha-blocker use is associated with decreased risk of sexual dysfunction. Urology. 2009;74(1):82–7.CrossRefPubMedPubMedCentral
61.
Committee APG, AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol. 2003;170(2 Pt 1):530–47.CrossRef
62.
Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998;51(6):892–900.CrossRefPubMed
63.
Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008;5(12):2917–24.CrossRefPubMed
64.
Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5(4):671–8.CrossRefPubMed
65.
Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, Shariat SF, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554–66.CrossRefPubMed
66.
Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C, Ankerst DP, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99(13):1025–35.CrossRefPubMed
67.
Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol. 2017;6(2):295–304.CrossRefPubMedPubMedCentral
68.
•• Roehrborn CG, et al. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018;121(4):647–58 This is the first study to prospectively assess sexual dysfunction in men with LUTS treated with either dutasteride/tamsulosin or placebo. While sexual dysfunction has typically been reported as an adverse event in prior studies, this study uses the Men’s Sexual Health Questionnaire as a primary endpoint. CrossRefPubMed
69.
Moncada I, Krishnappa P. Re: a prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Eur Urol. 2019;75(2):344–5.CrossRefPubMed
70.
Fusco F, Creta M. Sexual function in patients undergoing combination treatment with α1-adrenoceptor antagonists and 5α-reductase inhibitors: a step forward in a still-open debate. BJU Int. 2018;121(4):491–2.CrossRefPubMed
71.
Lourenco T, Shaw M, Fraser C, MacLennan G, N’Dow J, Pickard R. The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials. World J Urol. 2010;28(1):23–32.CrossRefPubMed
72.
Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol. 2017;72(6):986–97.CrossRefPubMed
73.
Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190(6):2161–7.CrossRef
74.
Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24(3):8802–13.
75.
McNicholas TA, Woo HH, Chin PT, Bolton D, Fernández Arjona M, Sievert KD, et al. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol. 2013;64(2):292–9.CrossRefPubMed
76.
Sønksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol. 2015;68(4):643–52.CrossRef
77.
Shore N. A review of the prostatic urethral lift for lower urinary tract symptoms: symptom relief, flow improvement, and preservation of sexual function in men with benign prostatic hyperplasia. Curr Bladder Dysfunct Rep. 2015;10(2):186–92.CrossRefPubMedPubMedCentral
78.
McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529–38.CrossRef
79.
McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2018;111:1–9.CrossRefPubMed
80.
Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int. 2016;117(6):923–9.CrossRef
81.
Abt D, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018;361:k2338.CrossRefPubMedPubMedCentral
82.
Pisco JM, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol. 2016;27(8):1115–22.CrossRef
83.
Pariser JJ, Packiam VT, Adamsky MA, Bales GT. Trends in simple prostatectomy for benign prostatic hyperplasia. Curr Urol Rep. 2016;17(8):57.CrossRefPubMed
84.
Pokorny M, Novara G, Geurts N, Dovey Z, de Groote R, Ploumidis A, et al. Robot-assisted simple prostatectomy for treatment of lower urinary tract symptoms secondary to benign prostatic enlargement: surgical technique and outcomes in a high-volume robotic Centre. Eur Urol. 2015;68(3):451–7.CrossRefPubMed
85.
Wang P, Xia D, Ye SY, Kong DB, Qin J, Jing TL, et al. Robotic-assisted urethra-sparing simple prostatectomy via an extraperitoneal approach. Urology. 2018;119:85–90.CrossRefPubMed
86.
Simone G, Misuraca L, Anceschi U, Minisola F, Ferriero M, Guaglianone S, et al. Urethra and ejaculation preserving robot-assisted simple prostatectomy: near-infrared fluorescence imaging-guided Madigan technique. Eur Urol. 2019;75(3):492–7.CrossRefPubMed
87.
Sountoulides P, Karatzas A, Gravas S. Current and emerging mechanical minimally invasive therapies for benign prostatic obstruction. Ther Adv Urol. 2019;11:1756287219828971.CrossRefPubMedPubMedCentral
88.
Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol. 2018;5(1):22–7.CrossRefPubMed
89.
Giona S, Ganguly I, Muir G. Urologists’ attitudes to sexual complications of LUTS/BPH treatments. World J Urol. 2018;36(9):1449–53.CrossRefPubMed
90.
Duan Y, Grady JJ, Albertsen PC, Helen Wu Z. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf. 2018;27(3):340–8.CrossRef
91.
Metadaten
Titel
The Complex Relationship Between Lower Urinary Tract Symptoms and Sexual Health
verfasst von
Hanson Zhao
Howard H. Kim
Publikationsdatum
01.10.2019
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 10/2019
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-019-0930-4

Weitere Artikel der Ausgabe 10/2019

Current Urology Reports 10/2019 Zur Ausgabe

Prostate Cancer (S Prasad, Section Editor)

Quality of Life–Focused Decision-Making for Prostate Cancer

Prostate Cancer (S Prasad, Section Editor)

The Microbiome and Prostate Cancer Risk

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Irreversible Electroporation for the Ablation of Prostate Cancer

Education (G Badalato, Section Editor)

Strategies for Attracting Women and Underrepresented Minorities in Urology

Education (G Badalato, Section Editor)

What Is Underlying Resident Burnout in Urology and What Can Be Done to Address this?

Prostate Cancer (S Prasad, Section Editor)

Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization

Neu im Fachgebiet Urologie

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise